Miguel A. Quintana, Cardiopulomonary Institute LW Randall, Cardiovascular, Asunción, Paraguay
Joaquín Perea, Sanatorio Guemes, Unidad Coronaria, Buenos Aires, Argentina
Ricardo Villarreal, Cardiopulomonary Institute LW Randall, Cardiovascular, Asunción, Paraguay; Sanatorio Guemes, Unidad Coronaria, Buenos Aires, Argentina
Arnaldo López-Ruiz, AdventHealth Orlando -– Department of Critical Care, Orlando, Florida, USA
Alexandra Arias, Instituto Nacional de Cardiología Ignacio Chávez, State of Mexico, Mexico
Yhaquelina Quispe, Hospital Obrero No 1, La Paz, Bolivia
Alex Rivera-Toquica, Clinica los Rosales, Risaralda, Colombia
Manuel Álvarez-Gaviria, Consejo de Emergencias y Cuidados Críticos Cardiovasculares, Sociedad Interamericana de Cardiología, Ciudad de México, México
Gonzalo Pérez, Servicio de Cardiología de la Clínica Olivos, Ciudad de Olivos, provincia de Buenos Aires, Argentina
Rafael Cortês, Hospital Sírio, Libanês Brasília, Cardiologia, Brasília, DF, Brazil
Roger Tenezaca, Hospital de especialidades Guayaquil Abel Gilbert Ponton, Guayaquil, Ecuador
Marildes Castro, Faculdade de Medicina, Universidade Federal de Minas Gerais, Cardiologia,Belo Horizonte, MG, Brazil
Iván Saavedra, Biocor Hospital de Doenças Cardiovasculares Ltda, Cardiologia, Belo Horizonte, MG, Brazil
Juan P. Costabel, Consejo de Emergencias Cardiovasculares; Sociedad Latinoamericana de Cardiología Intervencionista
Introduction: ST-elevation myocardial infarction (STEMI) remains a leading cause of cardiovascular mortality globally. The Latin STEMI registry conducted in 2024 aimed to evaluate reperfusion strategies and in-hospital mortality across America. Method: This observational, cross-sectional study included 575 STEMI patients from 40 centers in 13 countries in the Americas, collected from February to May 2024. Reperfusion strategies, treatment times, and clinical outcomes were analyzed. Results: Reperfusion therapy was administered to 95% of patients, with primary percutaneous coronary intervention in 56% and thrombolysis in 43%. Only 60% of patients treated with primary angioplasty and 40% of those treated with thrombolytics achieved door-to-balloon and door-to-needle times below 90 and 30 minutes, respectively. Conclusions: Despite reperfusion rates consistent with international benchmarks, significant challenges remain regarding treatment times and in-hospital mortality in the region. This registry underscores the need to enhance care networks and ensure equitable access to high-quality reperfusion strategies.
Keywords: Myocardial infarction. Angioplasty. Fibrinolytic agents. ST elevation myocardial infarction. IAMCEST.